Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

How I treat transplant-eligible patients with myelofibrosis

Nicolaus Kröger, Christine Wolschke, Nico Gagelmann

Blood (2023) 142 (20): 1683–1696.

https://doi.org/10.1182/blood.2023021218

Published: 2023

Journal Articles

Mutation Clearance of Driver Mutations after Transplantation for Myelofibrosis Predicts Outcome

Nico Gagelmann, Marie Quarder, Anita Badbaran, Christine Wolschke, Kristin Rathje, Mathias Schäfersküpper, Ameya Shrinivas Kunte, Evgeny Klyuchnikov, Radwan Massoud, Johanna Richter, Dietlinde Janson, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 630.

https://doi.org/10.1182/blood-2023-191242

Published: 2023

Journal Articles

Leukemic Stem Cells (LSCs) As Peri-Transplant MRD Assessment in AML Patients Undergoing Allogeneic Stem Cell Transplantation in CR

Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Petra Freiberger, Christine Wolschke, Francis A. Ayuk, Ulrike Bacher, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2023-188998

Published: 2023

Journal Articles

The Impact of Anti-T-Lymphocyte-Globulin Dosing on Gvhd in Matched Sibling Allogeneic Stemcell Transplantation

Radwan Massoud, Ameya Shrinivas Kunte, Evgeny Klyuchnikov, Anita Badbaran, Christian Niederwieser, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kröger

Blood (2023) 142 (Supplement 1): 7014.

https://doi.org/10.1182/blood-2023-188880

Published: 2023

Journal Articles

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

Radwan Massoud, Evgeny Klyuchnikov, Ameya Shrinivas Kunte, Christian Niederwieser, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kröger

Blood (2023) 142 (Supplement 1): 2156.

https://doi.org/10.1182/blood-2023-188745

Published: 2023

Journal Articles

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Kristin Rathje, Nico Gagelmann, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2023-185991

Published: 2023

Journal Articles

Spectrum of ASXL1 Mutations Show Similar Impact on Outcomes in Patients with Myelofibrosis Undergoing Transplantation

Nico Gagelmann, Anita Badbaran, Christine Wolschke, Mathias Schäfersküpper, Dietlinde Janson, Francis A. Ayuk, Boris Fehse, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2023-191280

Published: 2023

Journal Articles

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Nico Gagelmann, Anita Badbaran, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger

Blood (2023) 141 (23): 2901–2911.

https://doi.org/10.1182/blood.2023019630

Published: 2023

Includes: Supplemental data

Journal Articles

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Nico Gagelmann, Anita Badbaran, Rachel Beth Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Arnold Ganser, Christina Rautenberg, Bruno Cassinat, Felicitas R Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kroeger

Blood (2022) 140 (Supplement 1): 828–829.

https://doi.org/10.1182/blood-2022-158900

Published: 2022

Journal Articles

Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation

Nico Gagelmann, Anita Badbaran, Christine Wolschke, Raissa Adjallé, Dietlinde Janson, Carolina Berger, Evgeny Klyuchnikov, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2022) 140 (Supplement 1): 7672–7673.

https://doi.org/10.1182/blood-2022-170107

Published: 2022

Journal Articles

Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies

Ameya Shrinivas Kunte, Nico Gagelmann, Anita Badbaran, Carolina Berger, Radwan Massoud, Evgeny Klyuchnikov, Christine Wolschke, Dietlinde Janson, Ulrike Fritsche-Friedland, Boris Fehse, Nicolaus Kroeger, Francis A. Ayuk

Blood (2022) 140 (Supplement 1): 7531–7532.

https://doi.org/10.1182/blood-2022-168667

Published: 2022

Journal Articles

Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Ulrike Fritsche-Friedland, Maximilian Christopeit, Dietlinde Janson, Francis A. Ayuk, Christine Wolschke, Nicolaus Kröger

Blood (2021) 138 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2021-152148

Published: 2021

Journal Articles

Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis

Nico Gagelmann, Anita Badbaran, Markus Ditschkowski, Victoria Panagiota, Bruno Cassinat, Michael Heuser, Felicitas Thol, Christine Wolschke, Rachel B. Salit, Marie Robin, Dietrich W. Beelen, Bart L. Scott, Nicolaus Kroeger

Blood (2021) 138 (Supplement 1): 314.

https://doi.org/10.1182/blood-2021-152712

Published: 2021

Journal Articles

Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma Improved Overall Survival in Upfront Hematopoietic Stem Cell Transplantation — a Large Retrospective Study By the Chronic Malignancies Working Party of the EBMT

Blood (2018) 132 (Supplement 1): 3464.

https://doi.org/10.1182/blood-2018-99-114402

Published: 2018

Journal Articles

Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial

Blood (2018) 132 (Supplement 1): 661.

https://doi.org/10.1182/blood-2018-99-112614

Published: 2018

Journal Articles

High Cure Rate By Allogeneic Stem Cell Transplantation for Myelofibrosis Patients Aged 65 or Older

Giulia Daghia, MD PhD, Tatjana Zabelina, MD, Gaby Zeck, Ute-Marie von Pein, MD, Maximilian Christopeit, MD, Christine Wolschke, MD, Francis Ayuketang Ayuk, MD, Nicolaus Kroeger, MD

Blood (2018) 132 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2018-99-113255

Published: 2018

Journal Articles

Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis

Jeanne Palmer, MD, Heidi E. Kosiorek, MS, Christine Wolschke, MD, Veena D. S. Fauble, MD, Richard Butterfield, III, Holly Geyer, MD, Robyn M. Scherber, MD, Amylou C. Dueck, PhD, Allison Gathany, MD, Ruben A. Mesa, MD FACP, Nicolaus Kroeger, MD

Blood (2018) 132 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2018-99-111420

Published: 2018

Journal Articles

Reduced Intensity Allogeneic Stem Cell Transplantation for Younger Patients with Myelofibrosis

Daniele Mannina, MD, Christine Wolschke, MD, Tatjana Zabelina, MD, Gaby Zeck, Ute-Marie von Pein, MD, Francis Ayuketang Ayuk, MD, Nicolaus Kroeger, MD

Blood (2018) 132 (Supplement 1): 5783.

https://doi.org/10.1182/blood-2018-99-112137

Published: 2018

Journal Articles

Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study)

Blood (2018) 132 (Supplement 1): 208.

https://doi.org/10.1182/blood-2018-99-115932

Published: 2018

Journal Articles

Clonal Evolution of Myelofibrosis Patients in Relapse after Allogeneic Stem Cell Transplantation Revealed By Whole Exome Sequencing

Maximilian Christopeit, MD, Anita Badbaran, Malik Alawi, M. Sc., Christine Wolschke, Francis A Ayuk, Nicolaus Kröger

Blood (2017) 130 (Supplement 1): 2912.

https://doi.org/10.1182/blood.V130.Suppl_1.2912.2912

Published: 2017

NARROW

How I treat transplant-eligible patients with myelofibrosis

Mutation Clearance of Driver Mutations after Transplantation for Myelofibrosis Predicts Outcome

Leukemic Stem Cells (LSCs) As Peri-Transplant MRD Assessment in AML Patients Undergoing Allogeneic Stem Cell Transplantation in CR

The Impact of Anti-T-Lymphocyte-Globulin Dosing on Gvhd in Matched Sibling Allogeneic Stemcell Transplantation

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Spectrum of ASXL1 Mutations Show Similar Impact on Outcomes in Patients with Myelofibrosis Undergoing Transplantation

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation

Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies

Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis

Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma Improved Overall Survival in Upfront Hematopoietic Stem Cell Transplantation — a Large Retrospective Study By the Chronic Malignancies Working Party of the EBMT

Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial

High Cure Rate By Allogeneic Stem Cell Transplantation for Myelofibrosis Patients Aged 65 or Older

Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis

Reduced Intensity Allogeneic Stem Cell Transplantation for Younger Patients with Myelofibrosis

Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study)

Clonal Evolution of Myelofibrosis Patients in Relapse after Allogeneic Stem Cell Transplantation Revealed By Whole Exome Sequencing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only